Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Influenza A H7N7 vaccine (NIAID)
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
This is a live-attenuated influenza vaccine (LAIV) candidate developed by the National Institute of Allergy and Infectious Diseases (NIAID) to prevent avian influenza H7N7 infection. The vaccine is a 6:2 reassortant virus, containing the hemagglutinin (HA) and neuraminidase (NA) genes from the highly pathogenic avian influenza A/Netherlands/219/03 (H7N7) strain and the six internal protein genes from the cold-adapted (ca) A/Ann Arbor/6/60 (H2N2) master donor virus. It is designed to be administered intranasally to induce mucosal and systemic immunity, mimicking natural infection while remaining attenuated and temperature-sensitive. The vaccine was evaluated in Phase 1 clinical trials for safety and immunogenicity in healthy adults as part of pandemic preparedness efforts.
- Other names
- Live Influenza A Vaccine H7N7 (6-2) AA ca RecombinantLive Attenuated H7N7 Influenza VaccineInfluenza A H7N7 vaccine
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on Influenza A H7N7 vaccine (NIAID).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Influenza A H7N7 vaccine (NIAID).